[1] MALVE H, GOSWAMI P, ASALKAR A, et al.Role of Desmopressin in Bleeding Disorders: What Indian Physicians Need to Know[J]. Journal of The Association of Physicians of India, 2025, 73(1): 58-60. [2] EVERAERT K, HOLM-LARSEN T, BOU KHEIR G, et al.Potential Clinical Applications of Current and Future Oral Forms of Desmopressin (Review)[J]. Experimental and Therapeutic Medicine, 2024, 28(2): 1-21. [3] National Medical Products Administration Center for Drug Evaluation. Technical Guidelines for Pharmaceutical Research of Chemically Synthesized Polypeptide Drugs (Trial)[EB/OL]. (2023-02-17)[2025-07-19]. https://www.cde.org.cn/main/news/viewInfoCommon/7c105061d4d0f70dfa8e809725a63972. [4] WANG SR, ZHANG JL, BAI Y.Technical Requirements of Quality Research on Peptidechemical Generic Drug and Case Study[J].Chinese Journal of New Drugs(中国新药杂志), 2023, 32(9): 886-892. [5] CHEN XM, YUAN HX, MI PC, et al. A Synthetic Method of Desmo-pressin (一种去氨加压素的合成方法): China, CN112062813A[P].2020-12-11. [6] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People's Republic of China, Volume IV (中华人民共和国药典四部)[M]. Beijing: China Medical Science Press, 2020: 1798-1799. [7] United States Pharmacopeial Convention. United States Pharmacopeia-National Formulary, 43rd Edition, 2nd Supplement[M]. Rockville: United States Pharmacopeial Convention, Inc., 2020: 1265-1266. [8] European Directorate for the Quality of Medicines & HealthCare. European Pharmacopoeia 11.2[M]. Strasbourg: Council of Europe Publishing, 2023: 2488-2489. [9] British Pharmacopoeia Commission.British Pharmacopoeia 2025[M]. London: The Stationery Office, 2025. [10] LIU JC, WU ZJ, LIANG S.Application of Molecular Exclusion Chromatography in Drug Quality Control and Other Aspects[J]. Drug Standards of China(中国药品标准), 2023, 24(3): 275-280. [11] YUAN HX, CHEN L, YIN CL, et al. Method for the Synthesis of a Desmopressin Acetate Dimer Impurity: China, CN114133455A[P].2022-03-04. [12] XIAO T, WANG C, YAO SC, et al.Application of an HPLC Correction Factor Method in Pharmaceutical Analysis[J]. Acta Pharmaceutica Sinica(药学学报), 2020, 55(12): 2854-2861. [13] DAI J, ZHAO QJ, TONG Y.Discussion on Quality Control of Synthetic Peptide[J]. Pharmaceutical Biotechnology(药物生物技术), 2023, 30(1): 69-76. [14] HU YX,JIANG Y,HAN TJ,et al.Quality Control and Related Substances of Synthetic Peptide Drugs[J]. Chinese Journal of New Drugs(中国新药杂志), 2018, 27(5): 502-508. [15] MULAGAPATI SHR, PARUPUDI A, WITKOS T, et al.Size-Exclusion Chromatography as a Multi-Attribute Method for Process and Product Characterization of Adeno-Associated Virus[J]. Molecular Therapy-Methods & Clinical Development, 2024, 32(4): 1-13. [16] BAO Z, CHENG YC, LUO MZ, et al.Analysis of Aggregation Profile of Glucagon Using SEC-HPLC and FFF-MALS Methods[J]. PLoS ONE, 2024, 19(5): 1-15. |